Trial
NCT04431635
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Michigan Rogel Cancer Center
Collaborators
Bayer; Bristol-Myers Squibb; University of Michigan; Big Ten Cancer Research Consortium
Condition
Indolent Lymphoma
Intervention
Copanlisib
Why stopped
Loss of study funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-27